25 results on '"Stein, Stacey M."'
Search Results
2. Intrahepatic Cholangiocarcinoma: Socioeconomic Discrepancies, Contemporary Treatment Approaches and Survival Trends from the National Cancer Database
- Author
-
Uhlig, Johannes, Sellers, Cortlandt M., Cha, Charles, Khan, Sajid A., Lacy, Jill, Stein, Stacey M., and Kim, Hyun S.
- Published
- 2019
- Full Text
- View/download PDF
3. Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database
- Author
-
Uhlig, Johannes, Sellers, Cortlandt M., Stein, Stacey M., and Kim, Hyun S.
- Published
- 2019
- Full Text
- View/download PDF
4. Erythema Nodosum–like Eruption in the Setting of Sorafenib Therapy
- Author
-
Coleman, Emily L., Cowper, Shawn E., Stein, Stacey M., and Leventhal, Jonathan S.
- Published
- 2018
- Full Text
- View/download PDF
5. Clinical care in hepatocellular carcinoma: A mixed methods assessment of experiences and challenges of oncology professionals.
- Author
-
Jacobs, Ginny, Boyle, Deborah A., El‐Serag, Hashem B., Lewandowski, Robert J., Stein, Stacey M., Lazure, Patrice, and McFadden, Pam
- Subjects
HEPATOCELLULAR carcinoma ,MEDICAL personnel ,CLINICAL medicine ,PHYSICIANS' assistants ,NURSE practitioners ,INTERDISCIPLINARY communication ,ONCOLOGY - Abstract
Introduction: Healthcare providers (HCPs) may face numerous dilemmas in optimally screening, diagnosing, and treating patients with, and/or at risk for, hepatocellular carcinoma (HCC). This study aimed to achieve a greater understanding of the challenges in HCC care which in turn could delineate HCP educational opportunities within this oncologic sub‐specialty. Methods: A mixed‐methods approach was used to identify practice gaps and clinical barriers experienced by US‐based medical oncologists, hepatologists, oncology physician assistants, oncology nurse practitioners, and interventional radiologists involved in HCC care. The qualitative (semi‐structured interview) and quantitative (survey) data collection approaches were deployed sequentially with findings subsequently triangulated. Results: A total of 214 HCPs participated in this study. Analysis revealed challenges related to screening and diagnosing HCC, specifically in applying appropriate screening guidelines, and the optimal use and decisions related to diagnostic imaging and biopsy. Issues related to treatment selection included the application of existing HCC guidelines in treatment decision‐making, weighing risk/benefit ratios of various antineoplastics regimens (i.e., tyrosine kinase inhibitors‐TKIs, immunotherapy agents, chemotherapy), sequencing therapies, potential toxicity management, and optimally educating patients about their HCC. Conclusion: These findings highlight the educational needs of those involved in HCC care and provide a starting point for clinicians to both reflect on their practice and identify opportunities to enhance communication within the HCC team and between provider and patient. There is an opportunity to optimize continuing professional development interventions that address the identified gaps in clinical practice specifically related to teamwork and interdisciplinary communication. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Patient preferences regarding incidental genomic findings discovered during tumor profiling
- Author
-
Yushak, Melinda L., Han, Gang, Bouberhan, Sara, Epstein, Lianne, DiGiovanna, Michael P., Mougalian, Sarah S., Sanft, Tara B., Abu-Khalaf, Maysa M., Chung, Gina G., Stein, Stacey M., Goldberg, Sarah B., Pusztai, Lajos, and Hofstatter, Erin W.
- Published
- 2016
- Full Text
- View/download PDF
7. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity
- Author
-
Gunturu, Krishna S., Yao, Xiaopan, Cong, Xiangyu, Thumar, Jaykumar R., Hochster, Howard S., Stein, Stacey M., and Lacy, Jill
- Published
- 2013
- Full Text
- View/download PDF
8. Real-world association of HER2/ concordance with trastuzumab clinical benefit in advanced esophagogastric cancer.
- Author
-
Stein, Stacey M, Snider, Jeremy, Ali, Siraj M, Miksad, Rebecca A, Alexander, Brian M, Castellanos, Emily, Schrock, Alexa B, Madison, Russell, Swaminathan, Akshay, Venstrom, Jeffrey M, and McCusker, Margaret
- Abstract
Aim: To assess concordance between HER2 status measured by traditional methods and ERBB2 amplification measured by next-generation sequencing and its association with first-line trastuzumab clinical benefit in patients with advanced esophagogastric cancer. Methods: Retrospective analysis of HER2/ERBB2 concordance using a deidentified USA-based clinicogenomic database. Clinical outcomes were assessed for patients with HER2+ advanced esophagogastric cancer who received first-line trastuzumab. Results: Overall HER2/ERBB2 concordance was 87.5%. Among patients who received first-line trastuzumab, concordant HER2/ERBB2 was associated with longer time to treatment discontinuation (adjusted hazard ratio [aHR]: 0.63; 95% CI: 0.43-0.90) and overall survival (aHR: 0.51; 95% CI: 0.33-0.79). ERBB2 copy number ≥25 (median) was associated with longer time to treatment discontinuation (aHR: 0.56; 95% CI: 0.35-0.88) and overall survival (aHR: 0.52; 95% CI: 0.30-0.91). Conclusion: HER2/ERBB2 concordance and higher ERBB2 copy number predicted clinical benefit from trastuzumab. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma.
- Author
-
Sellers, Cortlandt M., Uhlig, Johannes, Ludwig, Johannes M., Pollak, Jeffrey S., Taddei, Tamar H., Stein, Stacey M., Lim, Joseph K., and Kim, Hyun S.
- Subjects
VIRAL hepatitis ,PROGNOSIS ,HEPATOCELLULAR carcinoma ,OVERALL survival ,HEPATITIS C ,PROPORTIONAL hazards models - Abstract
Background: Inflammation and the immune system significantly impact the development, progression, and treatment response of hepatocellular carcinoma (HCC). This retrospective study investigated the neutrophil-to-lymphocyte ratio (NLR) as a prognostic biomarker in Western patients with HCC in the setting of chronic viral hepatitis. Methods: Patients diagnosed with HCC from 2005 to 2016 were selected from a tertiary care institution. NLR was calculated within 30 days prior to treatment and dichotomized at the median. Kaplan–Meier overall survival (OS) curves and Cox hazard proportional models were utilized. Tumor and liver reserve parameters were included in multivariable analyses (MVA). Results: A total of 581 patients met inclusion criteria (median age 61.0 yr; 78.3% male; 66.3% Caucasian) with median OS = 34.9 mo. 371 patients (63.9%) had viral hepatitis, of which 350 had hepatitis C (94.3%). The low-NLR group (
- Published
- 2021
- Full Text
- View/download PDF
10. Yale Precision Medicine Tumor Board: reawakening the guardian of the genome
- Author
-
Grant, Michael J, Finberg, Karin E, Walther, Zenta, Stein, Stacey M, Lacy, Jill, Eder, Joseph P, and Goldberg, Sarah B
- Published
- 2022
- Full Text
- View/download PDF
11. Genomic mutations and histopathologic biomarkers in Y⁹⁰ radioembolization for chemorefractory colorectal liver metastases
- Author
-
Dendy, Meaghan S., Ludwig, Johannes M., Kokabi, Nima, Stein, Stacey M., Lacy, Jill, Hochster, Howard S., and Kim, Hyun S.
- Subjects
Medizin - Abstract
CA extern Background: To investigate mutational load and histologic biomarkers as prognostic factors in patients with chemorefractory colorectal liver metastases (CRLM) treated with Y-90 radioembolization therapy. Materials and Methods: Single institution retrospective study of patients with CRLM who received Y-90 radioembolization after undergoing molecular testing was performed. Patient demographics, systemic therapy regimens, tumor characteristics and overall survival were analyzed between patients with differing histopathologic and genomic status. PIK3CA, KRAS, NRAS, AKT1, MEK1, MLH1, MSH2, MSH6 and PMS2 were analyzed. Kaplan-Meier survival estimation and multivariate Cox regression were analyzed. Results: 23 patients underwent genomic analysis prior to Y-90. Eleven (47.8%) had mutations identified (MUT), and 12 were sequenced as wild type (WT) (52.2%). Median OS of 23 patients after Y-90 was 9.6 months (95% CI 6.67-16.23). Median OS from first Y-90 was significantly greater in WT patients (16.2 mo vs 6.5 mo; p =.0054). The survival difference between poorly differentiated tumors compared to all other histologic grades was significant (poor vs. well p=0.025, HR=26.8; poor vs. moderate p=.014, HR=23.07; poor vs. moderate/poor p=0.014, HR=23.68). When separated into 3 different groups (WT vs. MUT/moderate differentiation vs. MUT/poor differentiation) there was a difference in median OS observed (16.2 vs. 8.0 vs. 3.8 mos; p
- Published
- 2018
12. Inflammatory markers in intrahepatic cholangiocarcinoma: Effects of advanced liver disease.
- Author
-
Sellers, Cortlandt M., Uhlig, Johannes, Ludwig, Johannes M., Stein, Stacey M., and Kim, Hyun S.
- Subjects
LIVER diseases ,BILIARY tract cancer ,PROPORTIONAL hazards models ,VIRAL hepatitis - Abstract
Background: To investigate the neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), and systemic immune‐inflammation index (SII) as prognostic biomarkers in intrahepatic cholangiocarcinoma (ICC) with a focus on viral hepatitis and liver status. Methods: In this retrospective cohort study, patients from the institutional cancer registry with ICC from 2005 to 2016 were stratified by treatment group. Baseline inflammatory markers were dichotomized at the median. Overall survival (OS) was assessed via Kaplan‐Meier curves and Cox proportional hazard models. Multiple patient, liver, and tumor factors were included in the multivariable analysis (MVA). Results: About 131 patients (median age 65 years, 52% male, 76% Caucasian) had a median OS of 13.0 months. Resection/interventional oncology with/without systemic therapy had improved survival vs systemic therapy alone in Child‐Pugh A patients (P < 0.01). In Child‐Pugh B/C patients, this survival difference became nonsignificant (P = 0.22). Increased NLR and SII were associated with decreased survival (P < 0.01), while dichotomized PLR was not (P = 0.3). On MVA, increased NLR remained an independent prognostic factor (HR 1.6, P < 0.05). In Child‐Pugh class A (n = 94), low‐NLR had higher OS vs high‐NLR (25.4 vs 12.2 months, P < 0.01). In Child‐Pugh class B/C (n = 28), NLR did not have a significant effect on median OS (low‐ vs high‐NLR: 6.7 vs 2.9 months, P = 0.2). Child‐Pugh class acted as an effect modifier on MVA for NLR (P = 0.0124). Conclusions: The NLR has a stronger impact as a prognostic marker in ICC over the PLR and SII. This survival effect is decreased in advanced liver disease. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
13. The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insurance.
- Author
-
Sellers, Cortlandt M., Uhlig, Johannes, Ludwig, Johannes M., Taddei, Tamar, Stein, Stacey M., Lim, Joseph K., and Kim, Hyun S.
- Subjects
HEPATOCELLULAR carcinoma ,PROPORTIONAL hazards models ,LIVER disease diagnosis ,INSURANCE ,TUMOR classification - Abstract
Background: To investigate the impact of insurance status on outcomes in patients with hepatocellular carcinoma (HCC). Methods: Patients diagnosed with HCC in the cancer registry from 2005 to 2016 were retrospectively stratified by insurance group. Overall survival was assessed via Kaplan‐Meier curves and Cox proportional hazard models including potential confounders in multivariable analyses. Results: Seven hundred and sixty‐nine patients met inclusion criteria (median age 63 years, 78.8% male, 65.9% Caucasian). 44.5% had private insurance (n = 342), 29.1% had Medicare (n = 224), and 26.4% had Medicaid (n = 203). At diagnosis, Medicaid patients had higher rates of Child‐Pugh B (32.0%) and C disease (23.6%) vs Medicare (28.6% and 9.8%) and private insurance (26.9% and 6.7%, P < 0.0001) and higher MELD scores (median 11.0) vs Medicare (9.0) and private insurance (9.0, P = 0.0266). Across insurance groups, patients had similar distribution of American Joint Committee on Cancer stage, tumor size, and multifocal tumor burden. Patients with private insurance had the highest survival (median OS 21.9 months) vs Medicare (17.7 months) and Medicaid (13.0 months, overall P = 0.0061). On univariate analysis, Medicaid patients demonstrated decreased survival vs private insurance (HR 1.40, 95% CI: 1.146‐1.715, P = 0.0011). After adjustment for liver disease factors, this survival difference lost statistical significance (Medicaid vs private insurance, HR 1.02, 95% CI: 0.819‐1.266, P = 0.8596). Conclusion: Medicaid was associated with advanced liver disease at HCC diagnosis; however, insurance status is not an independent predictor of HCC survival. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
- Author
-
Stein, Stacey M, James, Edward S, Deng, Yanhong, Cong, Xiangyu, Kortmansky, Jeremy S, Li, Jia, Staugaard, Carol, Indukala, Doddamane, Boustani, Ann Marie, Patel, Vatsal, Cha, Charles H, Salem, Ronald R, Chang, Bryan, Hochster, Howard S, and Lacy, Jill
- Subjects
- *
ANTINEOPLASTIC agents , *ADENOCARCINOMA , *CAMPTOTHECIN , *CLINICAL trials , *COMPARATIVE studies , *FLUOROURACIL , *FOLINIC acid , *LIVER tumors , *LONGITUDINAL method , *LUNG tumors , *RESEARCH methodology , *MEDICAL cooperation , *METASTASIS , *ORGANOPLATINUM compounds , *PANCREATIC tumors , *PROGNOSIS , *RESEARCH , *RESEARCH funding , *SURVIVAL , *TUMOR classification , *PERITONEUM tumors , *EVALUATION research - Abstract
Background: Modifications of FOLFIRINOX are widely used despite the absence of prospective data validating efficacy in metastatic disease (metastatic pancreatic cancer (MPC)) or locally advanced pancreatic cancer (LAPC). We conducted a multicentre phase II study of modified FOLFIRINOX in advanced pancreatic cancer to assess the impact of dose attenuation in MPC and efficacy in LAPC.Methods: Patients with untreated MPC or LAPC received modified FOLFIRINOX (irinotecan and bolus 5-fluorouracil reduced by 25%). Adverse events (AEs) were compared with full-dose FOLFIRINOX. Response rate (RR), median progression-free survival (PFS) and median overall survival (OS) were determined.Results: In total, 31 and 44 patients with LAPC and MPC were enrolled, respectively. In MPC, efficacy of modified FOLFIRINOX was comparable with FOLFIRINOX with RR 35.1%, OS 10.2 months (95% CI 7.65-14.32) and PFS 6.1 months (95% CI 5.19-8.31). In LAPC, efficacy was notable with RR 17.2%, resection rate 41.9%, PFS 17.8 months (95% CI 11.0-23.9) and OS 26.6 months (95% CI 16.7, NA). Neutropenia (P<0.0001), vomiting (P<0.001) and fatigue (P=0.01) were significantly decreased. [(18)F]-Fluorodeoxyglucose positron emission tomography imaging response did not correlate with PFS or OS.Conclusions: In this first prospective study of modified FOLFIRINOX in MPC and LAPC, we observed decreased AEs compared with historical control patients. In MPC, the efficacy appears comparable with FOLFIRINOX. In LAPC, PFS and OS were prolonged and support the continued use of FOLFIRINOX in this setting. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
15. A Phase 2 Study of Oxaliplatin Combined With Continuous Infusion Topotecan for Patients With Previously Treated Ovarian Cancer.
- Author
-
Stein, Stacey M., Tiersten, Amy, Hochster, Howard S., Blank, Stephanie V., Pothuri, Bhavana, Curtin, John, Shapira, Ilan, Levinson, Benjamin, Ivy, Percy, Joseph, Benson, Guddati, Achuta Kumar, and Muggia, Franco
- Abstract
Phase 2 trials suggest that prolonged intravenous (IV) infusion of the topoisomerase 1 inhibitor topotecan may be less toxic than when given by standard IV bolus 5-day administration. Oxaliplatin exhibits efficacy in platinum-pretreated disease and shows preclinical synergy with topoisomerase 1 inhibitors. We sought to determine the efficacy and safety of oxaliplatin plus infusion topotecan in recurrent platinum-pretreated ovarian cancer.Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers previously treated with 1 to 2 prior regimens including platinum and taxane received oxaliplatin (85 mg/m
2 day 1 and day 15) and topotecan (0.4 mg/m2 per day) by continuous IV infusion over 14 days every 4 weeks. The primary objective of the trial was to estimate the objective response rate in platinum-resistant disease (stratum 1) and in platinum-sensitive disease (stratum 2). Toxicities were assessed in all patients.Thirty-eight patients received 144 cycles of therapy (median, 4; range, 1-6). The most common grade 3 and grade 4 toxicities included thrombocytopenia (grade 3, 37%; and grade 4, 19%), neutropenia (grade 3, 37%; grade 4, 11%), and anemia (grade 3, 15%). Response occurred in 4 of 19 patients in stratum I (21%; 95% confidence intervals, 6%-46%) and 9 of 19 patients in stratum 2 (47%; 95% CI, 24%-71%). Three in each stratum had lengthy complete responses.Biweekly oxaliplatin plus a 14-day continuous IV infusion of topotecan, given monthly, is an active regimen in platinum-pretreated ovarian cancer and merits additional evaluation. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
16. Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer.
- Author
-
Kim, Richard D., McDonough, Shannon, El-Khoueiry, Anthony B., Bekaii-Saab, Tanios S., Stein, Stacey M., Sahai, Vaibhav, Keogh, George P., Kim, Edward J., Baron, Ari D., Siegel, Abby B., Barzi, Afsaneh, Guthrie, Katherine A., Javle, Milind, and Hochster, Howard
- Subjects
- *
ANTINEOPLASTIC agents , *THERAPEUTIC use of antimetabolites , *CONFIDENCE intervals , *FLUOROURACIL , *HETEROCYCLIC compounds , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *DATA analysis software , *DESCRIPTIVE statistics , *EVALUATION ,BILE duct tumors - Abstract
The rationale for the evaluation of trametinib in advanced biliary cancer (BC) is based on the presence of mitogen-activated protein kinase alterations and on earlier promising results with MEK inhibitors in BC. Patients with histologically proven BC who progressed on gemcitabine/platinum were randomised to trametinib daily (arm 1) versus fluoropyrimidine therapy (infusional 5-fluorouracil or oral capecitabine, arm 2). The primary end-point was overall survival (OS). Secondary end-points included progression free survival (PFS) and response rate. A planned interim futility analysis of objective response was performed on the first 14 patients registered to the trametinib arm. The study was stopped early based on the lack of measurable response in the trametinib arm. A total of 44 eligible patients were randomised (24 patients in arm 1 and 20 patients in arm 2). Median age was 62 years and the primary sites of tumour were cholangiocarcinoma (68%) and gallbladder (32%). The overall response rate was 8% (95% CI 0%–19%) in arm 1 versus 10% (95% CI 0%–23%) in arm 2 (p >.99) Median OS was 4.3 months for arm 1 and 6.6 months for arm 2. The median PFS was 1.4 months for arm 1 and 3.3 months for arm 2. This is the first prospective randomised study of a targeted agent versus chemotherapy for the second-line treatment of BC. In this unselected population, the interim analysis result of unlikely benefit with trametinib resulted in early closure. • First randomized trial with targeted agent in refractory biliary cancer patients. • Trametinib was generally well tolerated in refractory biliary cancer patients. • There is unlikely benefit with trametinib in refractory biliary cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer.
- Author
-
Cecchini M, Zhang JY, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein SM, Kortmansky J, Johung KL, Bindra RS, LoRusso P, and Schalper KA
- Subjects
- Humans, Temozolomide pharmacology, Poly(ADP-ribose) Polymerase Inhibitors pharmacology, DNA Repair, O(6)-Methylguanine-DNA Methyltransferase, Alkylating Agents, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms drug therapy
- Abstract
Purpose: O
6 -methylguanine DNA methyltransferase ( MGMT )-silenced tumors reveal sensitivity to temozolomide (TMZ), which may be enhanced by PARP inhibitors. Approximately 40% of colorectal cancer has MGMT silencing and we aimed to measure antitumoral and immunomodulatory effects from TMZ and olaparib in colorectal cancer., Experimental Design: Patients with advanced colorectal cancer were screened for MGMT promoter hypermethylation using methylation-specific PCR of archival tumor. Eligible patients received TMZ 75 mg/m2 days 1-7 with olaparib 150 mg twice daily every 21 days. Pretreatment tumor biopsies were collected for whole-exome sequencing (WES), and multiplex quantitative immunofluorescence (QIF) of MGMT protein expression and immune markers., Results: MGMT promoter hypermethylation was detected in 18/51 (35%) patients, 9 received study treatment with no objective responses, 5/9 had stable disease (SD) and 4/9 had progressive disease as best response. Three patients had clinical benefit: carcinoembryonic antigen reduction, radiographic tumor regression, and prolonged SD. MGMT expression by multiplex QIF revealed prominent tumor MGMT protein from 6/9 patients without benefit, while MGMT protein was lower in 3/9 with benefit. Moreover, benefitting patients had higher baseline CD8+ tumor-infiltrating lymphocytes. WES revealed 8/9 patients with MAP kinase variants (7 KRAS and 1 ERBB2 ). Flow cytometry identified peripheral expansion of effector T cells., Conclusions: Our results indicate discordance between MGMT promoter hypermethylation and MGMT protein expression. Antitumor activity seen in patients with low MGMT protein expression, supports MGMT protein as a predictor of alkylator sensitivity. Increased CD8+ TILs and peripheral activated T cells, suggest a role for immunostimulatory combinations., Significance: TMZ and PARP inhibitors synergize in vitro and in vivo in tumors with MGMT silencing. Up to 40% of colorectal cancer is MGMT promoter hypermethylated, and we investigated whether TMZ and olaparib are effective in this population. We also measured MGMT by QIF and observed efficacy only in patients with low MGMT, suggesting quantitative MGMT biomarkers more accurately predict benefit to alkylator combinations., (© 2023 The Authors; Published by the American Association for Cancer Research.)- Published
- 2023
- Full Text
- View/download PDF
18. Real-world association of HER2/ ERBB2 concordance with trastuzumab clinical benefit in advanced esophagogastric cancer.
- Author
-
Stein SM, Snider J, Ali SM, Miksad RA, Alexander BM, Castellanos E, Schrock AB, Madison R, Swaminathan A, Venstrom JM, and McCusker M
- Subjects
- Aged, Esophageal Neoplasms mortality, Female, Gene Amplification, Gene Dosage, Humans, Male, Middle Aged, Receptor, ErbB-2 analysis, Retrospective Studies, Esophageal Neoplasms drug therapy, Receptor, ErbB-2 genetics, Trastuzumab therapeutic use
- Abstract
Aim: To assess concordance between HER2 status measured by traditional methods and ERBB2 amplification measured by next-generation sequencing and its association with first-line trastuzumab clinical benefit in patients with advanced esophagogastric cancer. Methods: Retrospective analysis of HER2/ ERBB2 concordance using a deidentified USA-based clinicogenomic database. Clinical outcomes were assessed for patients with HER2
+ advanced esophagogastric cancer who received first-line trastuzumab. Results: Overall HER2/ ERBB2 concordance was 87.5%. Among patients who received first-line trastuzumab, concordant HER2/ ERBB2 was associated with longer time to treatment discontinuation (adjusted hazard ratio [aHR]: 0.63; 95% CI: 0.43-0.90) and overall survival (aHR: 0.51; 95% CI: 0.33-0.79). ERBB2 copy number ≥25 (median) was associated with longer time to treatment discontinuation (aHR: 0.56; 95% CI: 0.35-0.88) and overall survival (aHR: 0.52; 95% CI: 0.30-0.91). Conclusion: HER2/ ERBB2 concordance and higher ERBB2 copy number predicted clinical benefit from trastuzumab.- Published
- 2021
- Full Text
- View/download PDF
19. Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers.
- Author
-
Klempner SJ, Bendell JC, Villaflor VM, Tenner LL, Stein SM, Rottman JB, Naik GS, Sirard CA, Kagey MH, Chaney MF, and Strickler JH
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized pharmacology, Female, Humans, Male, Middle Aged, Antibodies, Monoclonal, Humanized therapeutic use, Biomarkers, Tumor metabolism, Esophageal Neoplasms drug therapy, Programmed Cell Death 1 Receptor therapeutic use, Stomach Neoplasms drug therapy
- Abstract
Therapeutic combinations targeting innate and adaptive immunity and predictive biomarkers of response in esophagogastric cancer (EGC) are needed. We assessed safety and clinical utility of DKN-01 (a novel DKK1-neutralizing IgG4 antibody) combined with pembrolizumab and retrospectively determined DKK1 tumoral expression as a biomarker. Patients with advanced EGC received intravenous DKN-01 (150 or 300 mg) on days 1 and 15 with pembrolizumab 200 mg on day 1 in 21-day cycles. Clinical response was assessed by RECIST v1.1. Association of tumoral DKK1 mRNA expression ( H -score: high ≥ upper-tertile, low < upper-tertile) with response was assessed with PD-L1 levels as a covariate. Sixty-three patients received DKN-01 150 mg ( n = 2) or 300 mg ( n = 61) plus pembrolizumab. Common adverse events were fatigue, anemia, blood alkaline phosphatase elevation, aspartate aminotransferase elevation, and hyponatremia. Among evaluable anti-PD-1/PD-L1-naïve patients receiving DKN-01 300 mg and pembrolizumab, objective response rate (ORR) was 11.4% (5/44) and 18.5% (5/27) in patients with gastroesophageal junction or gastric cancer (GEJ/GC). Among response-evaluable anti-PD-1/PD-L1-naïve patients with GEJ/GC and known tumoral DKK1 expression, ORR was 50% in DKK1-high and 0% in DKK1-low patients, median PFS was 22.1 vs. 5.9 weeks (HR, 0.24; 95% CI, 0.08-0.67), respectively, and median OS was 31.6 weeks vs. 17.4 weeks (HR, 0.41; 95% CI, 0.16-1.07), respectively. Association of DKK1 expression with PFS was independent of PD-L1 expression (adjusted HR, 0.21; 95% CI, 0.06-0.69). DKN-01 combined with pembrolizumab was well tolerated with no new safety signals. Antitumor activity was enriched in anti-PD-1/PD-L1-naïve patients with GEJ/GC whose tumors expressed high DKK1., (©2021 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2021
- Full Text
- View/download PDF
20. Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions.
- Author
-
Dendy MS, Ludwig JM, Stein SM, and Kim HS
- Abstract
Image-guided locoregional therapies (LRTs) have long been a vital part of treatment regimens for hepatocellular carcinoma (HCC). Ablation, chemoembolization, and radioembolization are examples of commonly used treatment techniques for HCC. This review describes the various methods utilized to treat HCC in the field of interventional oncology and also focuses on new and novel treatment concepts being developed in the field including the use of novel immunotherapy agents and combination therapy of LRTs with immunotherapy., Competing Interests: The authors certify that all authors have no relevant financial conflict of interest for any aspect of the submitted manuscript. The authors certify that no authors at any time received payment or services from a third party for any aspect of the submitted manuscript. H.S.K. served on Advisory boards for Boston Scientific and SIRTex., (Copyright © 2019 by S. Karger AG, Basel.)
- Published
- 2019
- Full Text
- View/download PDF
21. Review and current state of radiation therapy for locally advanced pancreatic adenocarcinoma.
- Author
-
Blakaj A, Stein SM, Khan SA, and Johung KL
- Abstract
Pancreatic cancer is characterized by a high rate of metastatic spread and overall poor prognosis. Yet 30% of patients have progressive local disease at the time of death, and local progression can cause significant morbidity. Approximately 30-40% of patients present with locally advanced pancreatic cancer (LAPC) that is not surgically resectable, and the optimal treatment for these patients continues to evolve. The role of radiation in the management of LAPC is an area of controversy, and the recent LAP07 randomized trial reported no survival benefit of radiation following gemcitabine plus or minus erlotinib. However, the efficacy of modern systemic regimens has improved since the design of the LAP07 study, and radiation therapy may be of greater benefit in the context of more effective systemic therapy. Advances in radiation delivery including the increasing use of stereotactic body radiation therapy (SBRT) have the potential to improve outcomes through dose escalation and better treatment tolerability. In addition, the combination of radiation therapy and immune therapy is an area of promising research. These advances suggest that radiation therapy will continue to play an integral role in the management of LAPC., Competing Interests: Conflicts of Interest: The authors have no conflicts of interest to declare.
- Published
- 2018
- Full Text
- View/download PDF
22. Genomic mutations and histopathologic biomarkers in Y 90 radioembolization for chemorefractory colorectal liver metastases.
- Author
-
Dendy MS, Ludwig JM, Kokabi N, Stein SM, Lacy J, Hochster HS, and Kim HS
- Abstract
Background: To investigate mutational load and histologic biomarkers as prognostic factors in patients with chemorefractory colorectal liver metastases (CRLM) treated with Y-90 radioembolization therapy., Materials and Methods: Single institution retrospective study of patients with CRLM who received Y-90 radioembolization after undergoing molecular testing was performed. Patient demographics, systemic therapy regimens, tumor characteristics and overall survival were analyzed between patients with differing histopathologic and genomic status. PIK3CA, KRAS, NRAS, AKT1, MEK1, MLH1, MSH2, MSH6 and PMS2 were analyzed. Kaplan-Meier survival estimation and multivariate Cox regression were analyzed., Results: 23 patients underwent genomic analysis prior to Y-90. Eleven (47.8%) had mutations identified (MUT), and 12 were sequenced as wild type (WT) (52.2%). Median OS of 23 patients after Y-90 was 9.6 months (95% CI 6.67-16.23). Median OS from first Y-90 was significantly greater in WT patients (16.2 mo vs 6.5 mo; p =.0054). The survival difference between poorly differentiated tumors compared to all other histologic grades was significant (poor vs. well p=0.025, HR=26.8; poor vs. moderate p=.014, HR=23.07; poor vs. moderate/poor p=0.014, HR=23.68). When separated into 3 different groups (WT vs. MUT/moderate differentiation vs. MUT/poor differentiation) there was a difference in median OS observed (16.2 vs. 8.0 vs. 3.8 mos; p<.0001). Imaging response via RECIST criteria was significantly different between MUT and WT groups (p=0.02)., Conclusions: Mutational status and histopathologic grade may predict survival after Y-90 radioembolization therapy for CRLM., Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest. All authors have no financial any other relationship to disclose with any commercial organization that may have a direct or indirect interest in this manuscript.
- Published
- 2018
- Full Text
- View/download PDF
23. Does Chemoradiation Benefit Patients With Gastric Cancer Managed Without Surgery?
- Author
-
Johung KL and Stein SM
- Subjects
- Chemoradiotherapy standards, Humans, Medical Oncology methods, Neoplasm Staging, Palliative Care standards, Randomized Controlled Trials as Topic, Societies, Medical standards, Stomach Neoplasms mortality, Stomach Neoplasms pathology, Survival Analysis, Treatment Outcome, United States, Chemoradiotherapy methods, Medical Oncology standards, Palliative Care methods, Stomach Neoplasms therapy
- Published
- 2018
- Full Text
- View/download PDF
24. Management of sorafenib-related adverse events: a clinician's perspective.
- Author
-
Brose MS, Frenette CT, Keefe SM, and Stein SM
- Subjects
- Antineoplastic Agents therapeutic use, Carcinoma, Hepatocellular drug therapy, Carcinoma, Renal Cell drug therapy, Disease Management, Fatigue chemically induced, Fatigue therapy, Gastrointestinal Diseases chemically induced, Gastrointestinal Diseases therapy, Hand-Foot Syndrome therapy, Humans, Hypertension therapy, Kidney Neoplasms drug therapy, Liver Neoplasms drug therapy, Niacinamide adverse effects, Niacinamide therapeutic use, Phenylurea Compounds therapeutic use, Physicians, Sorafenib, Antineoplastic Agents adverse effects, Hand-Foot Syndrome etiology, Hypertension chemically induced, Niacinamide analogs & derivatives, Phenylurea Compounds adverse effects
- Abstract
Sorafenib, a tyrosine kinase inhibitor, is approved for the treatment of patients with unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC). It is being evaluated in phase II and III clinical trials, which include treatment as a single agent (locally advanced/metastatic radioactive iodine-refractory differentiated thyroid cancer [DTC]), as part of multimodality care (HCC), and in combination with chemotherapeutic agents (metastatic breast cancer). Sorafenib-related adverse events (AEs) that commonly occur across these tumor types include hand-foot skin reaction (HSFR), rash, upper and lower gastrointestinal (GI) distress (ie, diarrhea), fatigue, and hypertension. These commonly range from grade 1 to 3, per the Common Terminology Criteria for Adverse Events (CTCAE), and often occur early in treatment. The goal for the management of these AEs is to prevent, treat, and/or minimize their effects, thereby enabling patients to remain on treatment and improve their quality of life. Proactive management, along with ongoing patient education (before and during sorafenib treatment), can help to effectively manage symptoms, often without the need for sorafenib dose modification or drug holidays. Effective management techniques for common sorafenib-related AEs, as well other important disease sequelae not directly related to treatment, are presented. Recommendations and observations are based on physician/author experience and recommendations from published literature., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
25. Hepatocellular carcinoma: perspective of an oncologist.
- Author
-
Stein SM
- Subjects
- Antineoplastic Agents therapeutic use, Attitude of Health Personnel, Carcinoma, Hepatocellular drug therapy, Humans, Liver Neoplasms drug therapy, Medical Oncology, Niacinamide analogs & derivatives, Niacinamide therapeutic use, Phenylurea Compounds therapeutic use, Sorafenib, Carcinoma, Hepatocellular therapy, Liver Neoplasms therapy
- Abstract
The medical oncologist's perspective on hepatocellular carcinoma (HCC) is unique compared with their view on other solid tumors. A patient's underlying liver function should be factored into the selection of treatment options; therefore, a staging system that takes into account other clinical parameters other than only tumor characteristics is important. Sorafenib is currently the only FDA-approved chemotherapy drug for patients with HCC based on the data from the SHARP trial. It is important for oncologists to anticipate and treat the side effects of sorafenib treatment in order to help the patients continue the treatment. In addition, it is important to design clinical trials for HCC that have meaningful endpoints to improve our care for patients with HCC.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.